RECORDATI ET LEESPHARM ANNONCENT UN PARTENARIAT EN CHINE POUR LE ZANIDIP®
Monday, March 15, 2010 06:53:00 AM
Un contrat de distribution a été signé entre ces deux sociétés pour la commercialisation de comprimés de lercanidipine en Chine
Milan et Hong Kong, le 15 mars 2010 - Lee's Pharmaceutical Holdings Limited (GEM Stock : 8221. Site Web : http://www.leespharm.com) et Recordati S.p.A. (RECI.MI, REC IM, ISIN IT0003828271. Site Web : http://www.recordati.com), un groupe pharmaceutique européen, ont tous deux annoncé l'exécution d'une licence et d'un accord de fourniture pour un produit original de Recordati, le Zanidip® (lercanidipine), en Chine. Ce contrat attribue à Leespharm une licence exclusive de vente et de commercialisation du Zanidip® (comprimés de lercanidipine pour le traitement de l'hypertension) en République populaire de Chine.
"We are delighted to enter into this partnership with Leespharm for Zanidip®. This represents a new step in our international partnering strategy" said Giovanni Recordati, Chairman and CEO of Recordati. "Leespharm is a highly capable development and commercial organization in China and we look forward to working with Leespharm toward the common goal of enriching the distribution network in Asia for Zanidip® for the benefit of patients with hypertension."
"We are excited to announce this partnership with Recordati for Zanidip®. In the light of increasing prevalence of hypertension among Chinese, the favorable efficacy and safety profile of lercanidipine could be a preferable choice for antihypertensive treatment across a broad range of patients," stated Dr. Benjamin Li, the Chief Executive Officer of Leespharm. "China reports more than 200 million patients suffering from hypertension, it is expected that there will be an acceleration of penetration of Zanidip® in China market in the near future."
About Zanidip® (lercanidipine)
Zanidip® (lercanidipine) belongs to a group of medicines called calcium channel blockers (CCB's) which is widely prescribed for the treatment of hypertension. Zanidip® (lercanidipine) is a dihydropyridine (DHP) with an intrinsic long-acting hypertensive effect which exhibits a slow onset of action to help avoid reflex tachycardia. It is effective in reducing blood pressure over a 24 hour period with once daily dosing. Lercanidipine is effective across a wide range of patient groups, including the elderly as well as younger patients and diabetic patients with hypertension. It has equivalent antihypertensive efficacy to many other agents and is effective as initial monotherapy or in combination. The efficacy and tolerability profiles of lercanidipine make it a suitable choice for treating hypertension in a wide range of affected patients. Furthermore, lercanidipine causes less peripheral oedema than other CCB's at equivalent antihypertensive doses.
About Lee's Pharmaceutical
42 di 377-16/3/2010 10:040
gino80
N° messaggi: 614 -
Iscritto da: 03/3/2010
secondo voi dove arriva?
43 di 377-22/3/2010 08:420
antoniodangelo
N° messaggi: 7582 -
Iscritto da: 25/8/2009
attenzione a recordati stamattina... (credo che possa impennarsi)
44 di 377-22/3/2010 12:110
agiro
N° messaggi: 14334 -
Iscritto da: 29/8/2006
arrivera' dove vuol arrivare. resta uno dei titoli ke finora conti alla mano ha risentito meno di questa pseudo-crisi
45 di 377-22/3/2010 12:580
antoniodangelo
N° messaggi: 7582 -
Iscritto da: 25/8/2009
evidentemente mi sbagliavo... oggi non ne sto indovinando una
46 di 377-08/6/2010 22:400
agiro
N° messaggi: 14334 -
Iscritto da: 29/8/2006
bello pure questo
47 di 377-21/7/2010 23:220
agiro
N° messaggi: 14334 -
Iscritto da: 29/8/2006
mo vedem
48 di 377-03/8/2010 11:550
ciappola
N° messaggi: 4000 -
Iscritto da: 20/7/2007
uno dei migliori titoli del decennio.
49 di 377-19/1/2011 23:230
agiro
N° messaggi: 14334 -
Iscritto da: 29/8/2006
5 mln di italiani con l'influenza. ma ke dico , 20 mln con l'influenza, no no no, 50 mln con l'infuenza, ma skerziamo?? saranno 150 mln con l'influenza........
50 di 377-04/2/2011 10:400
fedeug
N° messaggi: 292 -
Iscritto da: 31/10/2006
dividendi?
51 di 377-04/2/2011 10:400
fedeug
N° messaggi: 292 -
Iscritto da: 31/10/2006
dividendi?
52 di 377-01/4/2011 16:370
lacarlo
N° messaggi: 13916 -
Iscritto da: 25/10/2008
qlkn sta su sto ttl?
53 di 377-Modificato il 27/5/2011 09:570
lacarlo
N° messaggi: 13916 -
Iscritto da: 25/10/2008
mikia ke azione...ma xkè la snobbate?
cerco di entrare, ma nn ripiega mai
54 di 377-04/7/2011 11:060
agiro
N° messaggi: 14334 -
Iscritto da: 29/8/2006
infedeli
55 di 377-05/7/2011 22:380
lacarlo
N° messaggi: 13916 -
Iscritto da: 25/10/2008
sto dietro da mesi, ma qst sale sempre....
56 di 377-04/11/2011 14:230
lacarlo
N° messaggi: 13916 -
Iscritto da: 25/10/2008
buy di assaggio a 6.03
57 di 377-04/11/2011 18:520
lacarlo
N° messaggi: 13916 -
Iscritto da: 25/10/2008
prese (200 pz.), vediamo che succede!
58 di 377-Modificato il 18/11/2011 16:330
lacarlo
N° messaggi: 13916 -
Iscritto da: 25/10/2008
piccolo incremento a 5.675
lunedì, dopo lo stacco, incremento del 50% l'intera posizione
59 di 377-01/12/2011 15:110
agiro
N° messaggi: 14334 -
Iscritto da: 29/8/2006
pure il supervirus in laboratorio dovevano creare
60 di 377-19/12/2011 16:360
lacarlo
N° messaggi: 13916 -
Iscritto da: 25/10/2008
Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Informazioni sulla discussione
Tutti
Torna alla Lista
Aggiorna Lista
Monday, March 15, 2010 06:53:00 AM
Un contrat de distribution a été signé entre ces deux sociétés pour la commercialisation de comprimés de lercanidipine en Chine
Milan et Hong Kong, le 15 mars 2010 - Lee's Pharmaceutical Holdings Limited (GEM Stock : 8221. Site Web : http://www.leespharm.com) et Recordati S.p.A. (RECI.MI, REC IM, ISIN IT0003828271. Site Web : http://www.recordati.com), un groupe pharmaceutique européen, ont tous deux annoncé l'exécution d'une licence et d'un accord de fourniture pour un produit original de Recordati, le Zanidip® (lercanidipine), en Chine. Ce contrat attribue à Leespharm une licence exclusive de vente et de commercialisation du Zanidip® (comprimés de lercanidipine pour le traitement de l'hypertension) en République populaire de Chine.
"We are delighted to enter into this partnership with Leespharm for Zanidip®. This represents a new step in our international partnering strategy" said Giovanni Recordati, Chairman and CEO of Recordati. "Leespharm is a highly capable development and commercial organization in China and we look forward to working with Leespharm toward the common goal of enriching the distribution network in Asia for Zanidip® for the benefit of patients with hypertension."
"We are excited to announce this partnership with Recordati for Zanidip®. In the light of increasing prevalence of hypertension among Chinese, the favorable efficacy and safety profile of lercanidipine could be a preferable choice for antihypertensive treatment across a broad range of patients," stated Dr. Benjamin Li, the Chief Executive Officer of Leespharm. "China reports more than 200 million patients suffering from hypertension, it is expected that there will be an acceleration of penetration of Zanidip® in China market in the near future."
About Zanidip® (lercanidipine)
Zanidip® (lercanidipine) belongs to a group of medicines called calcium channel blockers (CCB's) which is widely prescribed for the treatment of hypertension. Zanidip® (lercanidipine) is a dihydropyridine (DHP) with an intrinsic long-acting hypertensive effect which exhibits a slow onset of action to help avoid reflex tachycardia. It is effective in reducing blood pressure over a 24 hour period with once daily dosing. Lercanidipine is effective across a wide range of patient groups, including the elderly as well as younger patients and diabetic patients with hypertension. It has equivalent antihypertensive efficacy to many other agents and is effective as initial monotherapy or in combination. The efficacy and tolerability profiles of lercanidipine make it a suitable choice for treating hypertension in a wide range of affected patients. Furthermore, lercanidipine causes less peripheral oedema than other CCB's at equivalent antihypertensive doses.
About Lee's Pharmaceutical